Knockdown of brm, shg, ago, rhoGAPp190 and upf1 each significantly enhanced tumour sensitivity to trametinib plus PNU-74654 in both multigenic tumours, with the exception that shg had only weakly improved RAPp1 drug response (Fig. 6G,H). This evidence concerns the gene SMARCA2 and neoplasm.